The financing is achieved through an addendum to the loan financing agreement entered in November 2024 with Fenja Capital II A/S and the US-based investor Arena Investors, LP and additionally entering into a new loan agreement with Danish investors Venusat ApS and SAJ Finans ApS.

“This is an important continuation of the strategic financing that we completed in November 2024, allowing us to maintain flexibility while providing runway to reach key clinical and regulatory milestones for CS1 and CS014. We currently have two HDAC inhibitor programs in clinical development, a preclinical candidate advancing in its program, a growing IP portfolio, and strong scientific and regulatory momentum. With this financing, we are advancing two Phase II programs with promising drug candidates with potential to enhance and improve lives of patients with rare cardiovascular and pulmonary disease. Cereno Scientific is well-positioned for further growth and set-up for future clinical success,” says Sten R. Sörensen, CEO of Cereno Scientific.